Also known as Ala-Glu-Asp-Arg · AEDR tetrapeptide
Synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) in the Khavinson short-peptide bioregulator series, studied for effects on myocardial tissue.
Cardiogen (Ala-Glu-Asp-Arg) is the heart-directed member of the defined short-peptide bioregulator family, studied in the context of age-related myocardial decline in the originating research tradition.
Reported research examined cardiomyocyte markers and recovery endpoints in cardiac models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in one research tradition with limited independent replication, and it is not FDA-approved.
Proposed gene-regulatory modulation of myocardial gene expression.
Behind every vial of Cardiogen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cardiogen, specifically, is brought into being.
On paper, Cardiogen weighs in at roughly 489.5 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Cardiogen means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Cardiogen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Cardiogen proves itself: identity confirmed by mass spectrometry against its ~489.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cardiogen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Cardiogen to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Cardiogen, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Cardiogen is a synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator in the Khavinson short-peptide series.
The myocardium (heart muscle) — each bioregulator in the series is framed around a specific target tissue.
It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.